
|Articles|May 16, 2020
ASCRS 2020: Updates, improved injection technique from Eyepoint Pharmaceuticals
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' Sheryl Stevenson speaks with Eyepoint Pharmaceuticals' President/CEO Nancy Lurker and Chief Medical Officer Dario Paggiarino, MD, on the company's latest developments and research ahead of the ASCRS 2020 virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
AAO 2025: A study of retinal vasculitis events with intravitreal agents
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5


















































.png)


